$IBRX INSIGHTS →ImmunityBio shares jumped 30% again after positive feedback from the U.S. Food and Drug Administration.
Read the full research in the app
A subscription is required to access the full thread.
Open in the app →
$IBRX INSIGHTS →A subscription is required to access the full thread.
Open in the app →